组织工程与再生医学领域临床试验竞争格局分析OA

Objective To analyze clinical trial data in the field of tissue engineering and regenerative medicine from ClinicalTrials.gov and the Chinese Clinical Trial Registry(ChiCTR)to present the global and Chinese competitive landscape.Methods Data on clinical trials in the field of tissue engineering and regenerative medicine were collected from the two databases.A bibliometric analysis was conducted based on the number of registrations,countries or cities,clinical trial institutions,and sponsors.Results Based on ClinicalTrials.gov data,there were 582 registered clinical trials globally in the field of tissue engineering and regenerative medicine.Among 60 countries,the United States had 233 trials,China had 71,and all other countries had fewer than 30.Among more than 2000 clinical trial institutions,institutions such as Columbia University and University of California,Los Angeles in the United States stood out.Among 305 sponsors,55.74%were universities/hospitals,and 27.54%were enterprises.122 sponsors in the United States conducted 269 clinical trials,showing high activity.Based on ChiCTR data,China registered 97 clinical trials in this field.Among 29 cities,Shanghai registered 40 trials,Beijing registered 26,and other cities registered fewer than 10 trials.Among 76 clinical trial institutions and 45 sponsors,Beijing and Shanghai had the largest numbers,with institutions like Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine and Peking University School and Hospital of Stomatology being highly involved.Conclusion The number of registered clinical trials in the field of tissue engineering and regenerative medicine is on the rise globally and in China.The United States is in the leading position.There is still a gap between China and the United States,and international multi-center cooperation needs to be strengthened.